Venetoclax does not impair activated T-cell proliferation

Bone Marrow Transplant. 2021 Jul;56(7):1740-1742. doi: 10.1038/s41409-021-01245-6. Epub 2021 Mar 8.

Authors

Lama Siblany^{1

2}, Béatrice Gaugler^{1

2}, Nicolas Stocker^{1

2}, Laure Ricard^{1

2}, Yishan Ye¹, Mohamad Mohty^{1

2}, Florent Malard^{3

4}

Affiliations

¹ Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
² AP-HP, Hôpital Saint-Antoine, Service d'Hématologie Clinique et Thérapie Cellulaire, Paris, France.
³ Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France. florent.malard@inserm.fr.
⁴ AP-HP, Hôpital Saint-Antoine, Service d'Hématologie Clinique et Thérapie Cellulaire, Paris, France. florent.malard@inserm.fr.

PMID: 33686250
DOI: 10.1038/s41409-021-01245-6

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents*
Bridged Bicyclo Compounds, Heterocyclic* / pharmacology
Cell Proliferation
Lymphocyte Activation
Sulfonamides / pharmacology

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax